Home>>ω-Conotoxin GVIA (trifluoroacetate salt)

ω-Conotoxin GVIA (trifluoroacetate salt)

Catalog No.GC45241

ω-Conotoxin GVIA is a peptide originally isolated from the marine mollusk C.

Products are for research use only. Not for human use. We do not sell to patients.

ω-Conotoxin GVIA (trifluoroacetate salt) Chemical Structure

Size Price Stock
1mg
$427.00
Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

ω-Conotoxin GVIA is a peptide originally isolated from the marine mollusk C. geographus that acts as an N-type calcium channel blocker. It binds to human neocortical, rat hippocampal, and chick brain synaptic plasma membranes (IC50s = 4.6, 60, and 150 pM, respectively, in radioligand binding assays). ω-Conotoxin GVIA inhibits norepinephrine and acetylcholine release from human neocortical slices (IC50s = 14 and 3 nM, respectively) and calcium influx into chick synaptosomes by 92% when used at a concentration of 0.1 μM. It blocks electrically-evoked twitch responses of rat vas deferens and guinea pig ileum (IC50s = 9.8 and 55 nM, respectively) but does not affect the postjunctional contractile responses induced by norepinephrine on vas deferens or by carbamoylcholine on ileum. ω-Conotoxin GVIA does not affect potassium-induced contraction of rat aorta at concentrations up to 1 μM.

Reviews

Review for ω-Conotoxin GVIA (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 22 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for ω-Conotoxin GVIA (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.